Actovegin 40 mg / ml 5 ml 5 pcs.

1 ampoule contains:

active substance:

Actovegin® concentrate (in terms of dry deproteinized hemoderivat of calf blood) 1) - 200.0 mg;

excipient:

water for injection - up to 5 ml.

Pharmacotherapeutic group:

tissue regeneration stimulant

ATX code:

В06AB

pharmachologic effect

Pharmacodynamics

Antihypoxant. Actovegin® is a hemoderivat that is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass).

It has a positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of the plasma membranes of cells during ischemia and a decrease in the formation of lactate), thus having an antihypoxic effect, which begins to manifest itself at the latest 30 minutes after parenteral administration and reaches a maximum on average after 3 hours (2-6 hours). Actovegin® increases the concentration of adenosine triphosphate, adenosine diphosphate, phosphocreatine, as well as amino acids - glutamate, aspartate and gamma-aminobutyric acid.

The influence of Actovegin® on the absorption and utilization of oxygen, as well as insulin-like activity with the stimulation of glucose transport and oxidation, are significant in the treatment of diabetic polyneuropathy (DPN). In patients with diabetes mellitus and diabetic polyneuropathy, Actovegin® reliably reduces the symptoms of polyneuropathy (stitching pain, burning sensation, parasthesia, numbness in the lower extremities). Sensory disorders are objectively reduced, and the mental well-being of patients improves.

Pharmacokinet

Using pharmacokinetic methods, it is impossible to study the pharmacokinetic parameters of Actovegin®, since it consists only of physiological components that are usually present in the body.

To date, no decrease in the pharmacological effect of hemoderivatives has been found in patients with altered pharmacokinetics (for example, hepatic or renal failure, metabolic changes associated with old age, as well as metabolic features in newborns)

• Metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury).
• Peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers); diabetic polyneuropathy
• Wound healing (ulcers of various etiologies, burns, trophic disorders (bedsores), impaired wound healing processes).
• Prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy

The use of the drug in pregnant women did not cause adverse effects on the mother or fetus.

However, when used in pregnant women, the potential risk to the fetus must be considered.

• hypersensitivity to Actovegin® or similar drugs.
• decompensated heart failure;
• pulmonary edema;
• oliguria;
• anuria;
• fluid retention in the body.

Allergic reactions:

• skin rash;
• hyperemia of the skin;
• hyperthermia, up to anaphylactic shock.

It is currently unknown.

However, in order to avoid possible pharmaceutical incompatibility, it is not recommended to add other drugs to the Actovegin® infusion solution.

Depending on the severity of the clinical picture, the initial dose is 10-20 ml / day intravenously or intraarterially; then 5 ml intravenously or 5 ml intramuscularly.

Metabolic and vascular disorders of the brain: at the beginning of treatment, 10 ml intravenously daily for two weeks, then 5-10 ml intravenously 3-4 times a week for at least 2 weeks.

Ischemic stroke: 20-50 ml in 200-300 ml of the basic solution intravenously drip daily for 1 week, then 10-20 ml intravenously drip for 2 weeks.

Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml of the drug in 200 ml of the basic solution intraarterially or intravenously daily; the duration of treatment is about 4 weeks.

Wound healing: 10 ml intravenously or 5 ml intramuscularly daily or 3-4 times a week, depending on the healing process (in addition to local treatment with Actovegin in topical dosage forms).

Prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy: the average dose is 5 ml intravenously daily during the intervals of radiation exposure.

Radiation cystitis: 10 ml daily transurethral in combination with antibiotic therapy.

With multiple injections of the solution for infusion, the water-electrolyte balance of the blood plasma should be monitored.

Infusion solution and injection solution have a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the starting materials used, but this does not adversely affect the activity of the drug or its tolerance.

Do not use a cloudy solution or a solution containing foreign particles. After opening the vial (ampoule), the solution cannot be stored.

In the case of the intramuscular route of administration, the drug is administered slowly, no more than 5 ml. Due to the possibility of an anaphylactic reaction, it is recommended to carry out a test injection (2 ml / m).

Injection